BioCentury
ARTICLE | Clinical News

Edison reports Phase II data in Friedreich's ataxia

June 13, 2011 11:56 PM UTC

Edison Pharmaceuticals Inc. (San Jose, Calif.) said EPI-A0001 missed the primary endpoint in a Phase IIa trial to treat Friedreich's ataxia. The product did not significantly improve glucose dispositi...